Subclinical atrial fibrillation: Implications of recent trials for guideline updates?

Figure 3 Comparison of results of two recently published large direct oral anticoagulant randomized controlled trials in patients with subclinical AF-NOAH-AFNET with edoxaban & ARTESIA with apixaban, respectively. A: The primary efficacy outcome; B: The primary safety endpoint. The primary efficacy endpoint in the ARTESIA study was a composite of stroke/systemic embolism (SE), while in the NOAH AFNET-6 was cardiovascular death, stroke, or SE. The y axis represents the event rate measured in person-years. Similarly, major bleeding was the primary safety endpoint in ARTESIA, while in the NOAH-AFNET study, it was a combination of all-cause death or major bleeding. DOAC: Direct oral anticoagulant.